Novel therapeutic strategies to selectively kill cancer cells

Biochemical Pharmacology

Volumn 55, Issue 3, 1998, Pages 247-252

  Panchal, R G ^a  

^a Iowa Health System   (United States)

Author keywords

Cancer therapy; Immunotoxins; Monoclonal antibodies; Pore forming toxins

Indexed keywords

CELL SURFACE RECEPTOR; IMMUNOTOXIN; MONOCLONAL ANTIBODY;

CANCER CELL; CANCER THERAPY; CELL KILLING; CELL SURFACE; CYTOLYSIS; DRUG ACTIVATION; DRUG DEVELOPMENT; DRUG TARGETING; HUMAN; NONHUMAN; PRIORITY JOURNAL; REVIEW; SOLID TUMOR;

EID: 0032008099     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-2952(97)00240-2     Document Type: Article

References (71)

1. JC Bailar EM Smith Progress against cancer? New Engl J Med 314 1986 1226 1232
2. J Cairns The evolution of cancer research Cancer Cells 1 1989 1 8
3. RK Jain Barriers to drug delivery in solid tumors Sci Am 271 1994 58 65
4. RK Jain Delivery of molecular medicine to solid tumors Science 271 1996 1079 1080
5. S Paulie B Ehlin-Henriksson H Mellstedt H Koho H Ben-Aissa P Perlman A p50 surface antigen restricted to human urinary bladder carcinomas and B lymphocytes Cancer Immunol Immunother 20 1985 23 28
6. EA Clark JA Ledbetter Activation of human B cells mediated through two distinct cell surface antigens, Bp35 and Bp50 Proc Natl Acad Sci USA 83 1986 4494 4498
7. y-related cell surface antigens Cancer Res 50 1990 2183 2190
8. I Pastan ET Lovelace MG Gallo AV Rutherford JL Magnani MC Willingham Characterization of monoclonal antibodies B1 and B3 that react with mucinous adenocarcinomas Cancer Res 51 1991 3781 3787
9. WJ Gullick Prevalence of aberrant expression of the epidermal growth factor receptor in human cancers Br Med Bull 47 1991 87 98
10. NE Hynes Amplification and overexpression of the erbB -2 gene in human tumors Its involvement in tumor development, significance as a prognostic factor, and potential as a target for cancer therapy Semin Cancer Biol 4 1993 19 26
11. WG Stetler-Stevenson LA Liotta DE Kleiner Extracellular matrix 6 Role of matrix metalloproteinases in tumor invasion and metastasis FASEB J 7 1993 1434 1441
12. WL Monsky WT Chen Proteases of cell adhesion proteins in cancer Semin Cancer Biol 4 1993 251 258
13. JR MacDougall LM Matrisian Contributions of tumor and stromal matrix metalloproteinases to tumor progression, invasion and metastasis Cancer Metastasis Rev 14 1995 351 362
14. LM Coussens Z Werb Matrix metalloproteinases and the development of cancer Chem Biol 3 1996 895 904
15. LM Matrisian The matrix-degrading metalloproteinases Bioessays 14 1992 455 463
16. D Keppler M Abrahamson B Sordat Proteases and cancer Biochem Soc Trans 22 1994 43 49
17. BF Sloane Suicidal tumor proteases Nat Biotechnol 14 1996 826 827
18. TE Cawston E Mercer M de Silva BL Hazelman Metalloproteinases and collagenase inhibitors in rheumatoid synovial fluid Arthritis Rheum 27 1984 285 290
19. AM Cataldo RA Nixon Enzymatically active lysosomal proteases are associated with amyloid deposits in Alzheimer brain Proc Natl Acad Sci USA 87 1990 3861 3865
20. TA Waldmann JD White JA Carrasquillo JC Reynolds CH Paik OA Gansow MW Brechbiel ES Jaffe TA Fleisher CK Goldman LE Top R Bamford S Zaknoen E Roessler C Kasten-Sportes R England H Litou JA Johnson T Jackson-White A Manns B Hanchard RP Junghans DL Nelson Radioimmunotherapy of interleukin-2Rα-expressing adult T-cell leukemia with yttrium-90-labeled anti-Tac Blood 86 1995 4063 4075
21. FM Huennekens Tumor targeting Activation of prodrugs by enzyme–monoclonal antibody conjugates Trends Biotechnol 12 1994 234 239
22. PD Senter PM Wallace HP Svensson VM Vrudhula DE Kerr I Hellström KE Hellström Generation of cytotoxic agents by targeted enzymes Bioconjug Chem 4 1993 3 9
23. KD Bagshawe Antibody-directed enzyme prodrug therapy Clin Pharmacokinet 27 1994 368 376
24. PD Senter H Marquardt BA Thomas BD Hammock IS Frank HP Svensson The role of rat serum carboxylesterase in the activation of paclitaxel and camptothecin prodrugs Cancer Res 56 1996 1471 1474
25. PD Senter Activation of prodrugs by antibody–enzyme conjugates A new approach to cancer therapy FASEB J 4 1990 188 193
26. DE Kerr GJ Schreiber VM Vrudhula HP Svensson I Hellström KE Hellström PD Senter Regressions and cures of melanoma xenografts following treatment with monoclonal antibody β-lactamase conjugates in combination with anticancer prodrugs Cancer Res 55 1995 3558 3563
27. NL Krinick Y Sun D Joyner JD Spikes RC Straight J Kopecek A polymeric drug delivery system for the simultaneous delivery of drugs activatable by enzymes and/or light J Biomater Sci Polym Ed 5 1994 303 324
28. DD Lasic D Papahadjopoulos Liposomes revisited Science 267 1995 1275 1276
29. G Gregoriadis Engineering liposomes for drug delivery Progress and problems Trends Biotechnol 13 1995 527 537
30. DD Lasic Doxorubicin in sterically stabilized liposomes Nature 380 1996 561 562
31. S Yemul C Berger A Estabrook S Suarez R Edelson H Bayley Selective killing of T lymphocytes by phototoxic liposomes Proc Natl Acad Sci USA 84 1987 246 250
32. U Brinkmann Y Reiter S-H Jung B Lee I Pastan A recombinant immunotoxin containing a disulfide-stabilized Fv fragment Proc Natl Acad Sci USA 90 1993 7538 7542
33. Y Reiter U Brinkmann KO Webber S-H Jung B Lee I Pastan Engineering interchain disulfide bonds into conserved framework regions of Fv fragments Improved biochemical characteristics of recombinant immunotoxins containing disulfide-stabilized Fv Protein Eng 7 1994 697 704
34. Y Reiter U Brinkmann B Lee I Pastan Engineering antibody Fv fragments for cancer detection and therapy Disulfide-stabilized Fv fragments Nat Biotechnol 14 1996 1239 1245
35. ES Ward D Gussow AD Griffiths PT Jones G Winter Binding activities of a repertoire of single immunoglobulin variable domains secreted from Escherichia coli Nature 341 1989 544 546
36. C Hamers-Casterman T Atarhouch S Muyldermans G Robinson C Hamers E Bajyana Songa N Bendahman R Hamers Naturally occurring antibodies devoid of light chains Nature 363 1993 446 448
37. J Davies L Riechmann ‘Camelising’ human antibody fragments NMR studies on VH domains FEBS Lett 339 1994 285 290
38. J Davies L Riechmann Single antibody domains as small recognition units Design and in vitro antigen selection of camelized, human, VH domains with improved protein stability Protein Eng 9 1996 531 537
39. MW Fanger PM Guyre Bispecific antibodies for targeted cellular cytotoxicity Trends Biotechnol 9 1991 375 380
40. M Schmidt NE Hynes B Groner W Wels A bivalent single-chain antibody-toxin specific for ErbB-2 and the EGF receptor Int J Cancer 65 1996 538 546
41. KD Bagshawe Towards generating cytotoxic agents at cancer sites Br J Cancer 60 1989 275 281
42. L Riechmann M Clark H Waldmann G Winter Reshaping human antibodies for therapy Nature 332 1988 323 327
43. MS Co C Queen Humanized antibodies for therapy Nature 351 1991 501 502
44. I Benhar EA Padlan S-H Jung B Lee I Pastan Rapid humanization of the Fv of monoclonal antibody B3 by using framework exchange of the recombinant immunotoxin B3(Fv)-PE38 Proc Natl Acad Sci USA 91 1994 12051 12055
45. I Pastan V Chaudhary DJ FitzGerald Recombinant toxins as novel therapeutic agents Annu Rev Biochem 61 1992 331 354
46. S Bhakdi J Tranum-Jensen Damage to cell membranes by pore-forming bacterial cytolysins Prog Allergy 40 1988 1 43
47. S Bhakdi H Bayley A Valeva I Walev B Walker U Weller M Kehoe M Palmer Staphyloccocal alpha-toxin, streptolysin-O, and Escherichia coli hemolysin Prototypes of pore-forming bacterial cytolysins Arch Microbiol 165 1996 73 79
48. GJ Boulnois JC Paton TJ Mitchell PW Andrew Structure and function of pneumolysin, the multifunctional thiol-activated toxin of Streptococcus pneumoniae Mol Microbiol 5 1991 2611 2616
49. JT Buckley Crossing three membranes Channel formation by aerolysin FEBS Lett 307 1992 30 33
50. C-C Liu CM Walsh JD-E Young Perforin Structure and function Immunol Today 16 1995 194 201
51. G Belmonte C Pederzolli P Macek G Menestrina Pore formation by the sea anemone cytolysin equinatoxin II in red blood cells and model lipid membranes J Membr Biol 131 1993 11 22
52. S Bhakdi U Weller I Walev E Martin D Jonas M Palmer A guide to the use of pore-forming toxins for controlled permeabilization of cell membranes Med Microbiol Immunol ( Berl ) 182 1993 167 175
53. T Takuma T Ichida Catalytic subunit of protein kinase A induces amylase release from streptolysin O-permeabilized parotid acini J Biol Chem 269 1994 22124 22128
54. C-Y Chang B Niblack B Walker H Bayley A photogenerated pore-forming protein Chem Biol 2 1995 391 400
55. U Brinkmann I Pastan Immunotoxins against cancer Biochim Biophys Acta 1198 1994 27 45
56. I Hellström KE Hellström CB Siegall PA Trail Immunoconjugates and immunotoxins for therapy of carcinomas Adv Pharmacol 33 1995 349 388
57. I Pastan LH Pai U Brinkmann DJ FitzGerald Recombinant toxins New therapeutic agents for cancer Ann NY Acad Sci 758 1995 345 354
58. ML Grossbard OW Press FR Appelbaum ID Bernstein LM Nadler Monoclonal antibody-based therapies of leukemia and lymphoma Blood 80 1992 863 878
59. FM Uckun Immunotoxins for the treatment of leukaemia Br J Haematol 85 1993 435 438
60. LH Pai R Wittes A Setser MC Willingham I Pastan Treatment of advanced solid tumors with immunotoxin LMB-1 An antibody linked to Pseudomonas exotoxin Nat Med 2 1996 350 353
61. VS Byers RW Baldwin Rationale for clinical use of immunotoxins in cancer and autoimmune disease Semin Cell Biol 2 1991 59 70
62. AD Avila CM de Acosta A Lage A carcinoembryonic antigen-directed immunotoxin built by linking a monoclonal antibody to a hemolytic toxin Int J Cancer 43 1989 926 929
63. AD Avila CM de Acosta A Lage A new immunotoxin built by linking a hemolytic toxin to a monoclonal antibody specific for immature T lymphocytes Int J Cancer 42 1988 568 571
64. A Chovnick WP Schneider JY Tso C Queen CN Change A recombinant, membrane-acting immunotoxin Cancer Res 51 1991 465 467
65. C Pederzolli G Belmonte MD Serra P Macek G Menestrina Biochemical and cytotoxic properties of conjugates of transferrin with equinatoxin II, a cytolysin from a sea anemone Bioconjug Chem 6 1995 166 173
66. SAS Al-yahyaee DJ Ellar Cell targeting of a pore-forming toxin, CytA δ-endotoxin from Bacillus thuringiensis subspecies israelensis , by conjugating CytA with anti-Thy1 monoclonal antibodies and insulin Bioconjug Chem 7 1996 451 460
67. S Bhakdi J Tranum-Jensen Alpha-toxin of Staphylococcus aureus Microbiol Rev 55 1991 733 751
68. B Walker M Krishnasastry H Bayley Functional complementation of staphylococcal α-hemolysin fragments Overlaps, nicks and gaps in the glycine-rich loop J Biol Chem 268 1993 5285 5292
69. B Walker H Bayley A pore-forming protein with a protease-activated trigger Protein Eng 7 1994 91 97
70. H Bayley Pore-forming proteins with built-in triggers and switches Bioorg Chem 23 1995 340 354
71. RG Panchal E Cusack S Cheley H Bayley Tumor protease-activated, pore-forming toxins from a combinatorial library Nat Biotechnol 14 1996 852 856